Evidence map›Paper›PMID 36545214›Full record

ArticleFrontiers in chemistry2022

YH29407 with anti-PD-1 ameliorates anti-tumor effects

Dong Kwon Kim, Chun-Bong Synn, Seung Min Yang, Seongsan Kang, Sujeong Baek, Se-Woong Oh, Gyu-Jin Lee, Ho-Woong Kang, Young-Sung Lee, Jong Suk Park and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 6 institutions in 1 country.

Dong Kwon KimSeverance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea.
Chun-Bong SynnSeverance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea.
Seung Min YangDepartment of Research Support, Yonsei Biomedical Research Institute, Yonsei University College of Medicine, Seoul, South Korea.
Seongsan KangJEUK Institute for Cancer Research, JEUK Co., Ltd., Gumi, South Korea.
Sujeong BaekDepartment of Research Support, Yonsei Biomedical Research Institute, Yonsei University College of Medicine, Seoul, South Korea.
Se-Woong OhYuhan R&D Institute, Yuhan Corporation, Seoul, South Korea.
Gyu-Jin LeeYuhan R&D Institute, Yuhan Corporation, Seoul, South Korea.
Ho-Woong KangYuhan R&D Institute, Yuhan Corporation, Seoul, South Korea.
Young-Sung LeeYuhan R&D Institute, Yuhan Corporation, Seoul, South Korea.
Jong Suk ParkYuhan R&D Institute, Yuhan Corporation, Seoul, South Korea.
Jae Hwan KimSeverance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea.
Youngseon ByeonSeverance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea.
Young Seob KimSeverance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea.
Doo Jae LeeWide River Institute of Immunology, Seoul National University, Hongcheon, South Korea.
Hyun-Woo KimWide River Institute of Immunology, Seoul National University, Hongcheon, South Korea.
June Dong ParkWide River Institute of Immunology, Seoul National University, Hongcheon, South Korea.
Sung Sook LeeDepartment of Hematology-Oncology, Inje University Haeundae Paik Hospital, Busan, Korea.
Ji Yun LeeDivision of Medical Oncology, Department of Internal Medicine and Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Jii Bum LeeDivision of Medical Oncology, Department of Internal Medicine and Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Chang Gon KimDivision of Medical Oncology, Department of Internal Medicine and Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Min Hee HongDivision of Medical Oncology, Department of Internal Medicine and Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Sun Min LimDivision of Medical Oncology, Department of Internal Medicine and Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Hey Ryun KimDivision of Medical Oncology, Department of Internal Medicine and Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Kyoung-Ho PyoSeverance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea.
Byoung Chul ChoDivision of Medical Oncology, Department of Internal Medicine and Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Yonsei University · KRYuhan University · KRSeoul National University · KRInje University Haeundae Paik Hospital · KRJeuk (South Korea) · KRSeverance Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among cancer cells, indoleamine 2, 3-dioxygenase1 (IDO1) activity has been implicated in improving the proliferation and growth of cancer cells and suppressing immune cell activity. IDO1 is also responsible for the catabolism of tryptophan to kynurenine. Depletion of tryptophan and an increase in kynurenine exert important immunosuppressive functions by activating regulatory T cells and suppressing CD8

Indexed as

colon cancerIDO1immunotherapykynureninemolecule inhibitortryptophan

Identifiers

PMID36545214
PMCPMC9761775
OpenAlexW4311529084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.